Moderna is working with COVAX on a tiered pricing proposal. He said that the global manufacturing capacity for vaccines is quite abundant for billions of doses.
The company had almost $4.0 billion in cash at the end of the quarter, including more than $1 billion in deferred revenues connected to supply agreements with government agencies for future COVID-19 vaccine supply.
Takeda will import and distribute Moderna's shot, dubbed mRNA-1273, starting in the first half of next year, as well as handle local regulatory approvals, the drugmaker said. He said that before bringing this vaccine to the market in India, we have to see that the trial has been completed in the United Kingdom as well.
"Clover Biopharmaceuticals from Australia is now also being evaluated by the vaccine experts panel;" he added. It will be followed by some 500 million to one billion doses in 2021.
Now, Moderna has initiated the rolling submission of mRNA-1273 data for rolling review, in consideration of potential authorisation by the MHRA.
According to Business Insider, trades for Moderna were higher by as much as 13 percent while BioNtech went up 11 percent.
As reported by various television channels, the priority plan for distributing the vaccine is already in place.
As of 22 October, over 25,650 subjects received their second dose of the vaccine.
Domingo said the public can regularly check updates on COVID-19 vaccines through their tracker on the FDA website.
The report had also said that the trial is expected to restart by around 10 November.
"From a distribution standpoint, we're ready", Dr. Tal Zaks, Moderna's chief medical officer, told investors on a Thursday conference call.
It is important for drugmakers to test their vaccines on children, said US Food and Drug Administration (FDA). "So my issue is oversight - making sure all the protocols are being followed, any adverse effects that may happen with the vaccine itself", said Fiel.